Blogs

Edited by Ana Carrizosa Anderson and Dario Vignali

Inspired by the SITC session “Immune Checkpoints – Beyond PD-1,” JITC continues the impetus of recognizing a widening range of checkpoint targets that are advancing the field forward. Comprised of several authoritative reviews of checkpoints beyond PD-1, this series promotes the tremendous research that is opening new pathways for treating patients with cancer. 

• LAG-3: from molecular functions to clinical applications (13 Sept 2020)
• TIGIT in cancer immunotherapy (7 Sept 2020)
• Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy (15 July 2020)
• Tim-3 finds its place in the cancer immunotherapy landscape (29 June 2020)
• Lifting the innate immune barriers to antitumor immunity (8 April 2020)
• Master protocols in immuno-oncology: do novel drugs deserve novel designs? (1 April 2020)
• On the mechanism of anti-CD39 immune checkpoint therapy (24 Feb 2020)
• Monalizumab: inhibiting the novel immune checkpoint NKG2A (1 Dec 2019)